TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18815018

Group type: EXPERIMENTAL
Intervention: Willow bark extract
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 90
Study: 15739554

Group type: EXPERIMENTAL
Intervention: IL13-PE38QQR before and after tumor resection
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: IL13-PE38QQR after tumor resection
Number of subjects: 14
Study: 12870164

Group type: EXPERIMENTAL
Intervention: High-dose Caiapo (4 g/d)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low-dose Caiapo (2 g/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Caiapo (both doses)
Number of subjects: 18
Study: 11285043

Group type: EXPERIMENTAL
Intervention: HRT (2 mg oestradiol valerate for the first 3 months, with the addition of 10 mg medroxyprogesterone for 10 days every third month thereafter)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 51
Study: 9109825

Group type: EXPERIMENTAL
Intervention: Two-solution rinse
Number of subjects: 13

Group type: COMPARATOR
Intervention: NaF rinse (12 mmol/L, 228 ppm)
Number of subjects: 13
Study: 8510705

Group type: EXPERIMENTAL
Intervention: White men
Number of subjects: 2181

Group type: EXPERIMENTAL
Intervention: Black men
Number of subjects: 2181

Group type: EXPERIMENTAL
Intervention: White women
Number of subjects: 2181

Group type: EXPERIMENTAL
Intervention: Black women
Number of subjects: 2181

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 2181
Study: 3105364

Group type: EXPERIMENTAL
Intervention: Programmed Unit of Instruction (PUI) on infection control principles
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no PUI)
Number of subjects: 40
Study: 29870595

Group type: EXPERIMENTAL
Intervention: Perampanel 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel 6 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel (2-6 mg)
Number of subjects: 0
Study: 25977313

Group type: EXPERIMENTAL
Intervention: Fenoldopam (D1-like receptor agonist) during high NaCl diet
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fenoldopam (D1-like receptor agonist) during low NaCl diet
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fenoldopam with enalapril (ACE inhibitor) during low NaCl diet
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fenoldopam during high NaCl diet
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fenoldopam during low NaCl diet
Number of subjects: 7
Study: 25687147

Group type: EXPERIMENTAL
Intervention: Sucrose plus radiant warmth
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sucrose alone
Number of subjects: 29
Study: 24168259

Group type: EXPERIMENTAL
Intervention: HBIG + recombinant HBV vaccine
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo + recombinant HBV vaccine
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Overall outcomes at 24 months
Number of subjects: 259
Study: 19940005

Group type: EXPERIMENTAL
Intervention: HER2/neu overexpression (3+ protein expression)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: HER2/neu overexpression
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: LMVD
Number of subjects: 150
Study: 18795988

Group type: EXPERIMENTAL
Intervention: 25 mg/wk testosterone enanthate
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 50 mg/wk testosterone enanthate
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 125 mg/wk testosterone enanthate
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 300 mg/wk testosterone enanthate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 16374438

Group type: EXPERIMENTAL
Intervention: Antibiotic lock solution (cefazolin 10 mg/ml, gentamicin 5 mg/ml, heparin 1000 U/ml)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Heparin lock solution (heparin 1000 U/ml)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Antibiotic lock solution
Number of subjects: 120

Group type: COMPARATOR
Intervention: Heparin lock solution
Number of subjects: 120
Study: 12749507

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg orally once daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fenofibrate 67 mg orally TID
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rosuvastatin + Fenofibrate (dosed as above)
Number of subjects: 14
Study: 10768324

Group type: EXPERIMENTAL
Intervention: CsA 0.05%
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: CsA 0.1%
Number of subjects: 877

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 877
Study: 8807105

Group type: EXPERIMENTAL
Intervention: Allogeneic BMT (alloBMT)
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 730
Study: 31187226

Group type: EXPERIMENTAL
Intervention: Cryptosporidium parvum infection in calves with diarrhea
Number of subjects: 1073

Group type: EXPERIMENTAL
Intervention: GP60 subtyping of C. parvum isolates
Number of subjects: 1073
Study: 30260897

Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography-guided PEEP
Number of subjects: 40

Group type: COMPARATOR
Intervention: Institutional PEEP (4 cm H2O)
Number of subjects: 40
Study: 27028913

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (Vivitrol) for 24 weeks
Number of subjects: 308

Group type: COMPARATOR
Intervention: Usual treatment (brief counseling and referrals for community treatment programs)
Number of subjects: 308
Study: 24953333

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m²) plus cisplatin (75 mg/m²) followed by gefitinib maintenance
Number of subjects: 236

Group type: COMPARATOR
Intervention: Gefitinib monotherapy (250 mg/day)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Pemetrexed-cisplatin followed by gefitinib maintenance
Number of subjects: 236

Group type: COMPARATOR
Intervention: Gefitinib monotherapy
Number of subjects: 236
Study: 22762856

Group type: EXPERIMENTAL
Intervention: Test formulation (571-mg metformin acetate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference formulation (500-mg metformin hydrochloride)
Number of subjects: 30
Study: 18089552

Group type: EXPERIMENTAL
Intervention: Online psychoeducational support program
Number of subjects: 190
Study: 17044764

Group type: EXPERIMENTAL
Intervention: Advanced practice nurse (APN) strategies for coordinating care during transition from hospital to home
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 12885448

Group type: EXPERIMENTAL
Intervention: 35Gy in ten fractions
Number of subjects: 0

Group type: COMPARATOR
Intervention: 60Gy in 30 fractions
Number of subjects: 0
Study: 10680787

Group type: EXPERIMENTAL
Intervention: Prednisone (20 mg daily for 4 weeks, then 10 mg daily for 1 year, followed by gradual withdrawal over 16 weeks)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 138
Study: 9314342

Group type: EXPERIMENTAL
Intervention: House dust mite avoidance treatment (Acarosan applied to floors, impermeable covers for mattresses and bedding)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: House dust mite avoidance treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (water applied to floors, cotton covers for mattresses)
Number of subjects: 29
Study: 8153034

Group type: EXPERIMENTAL
Intervention: Systematic patient education about cough
Number of subjects: 5890

Group type: COMPARATOR
Intervention: Control practices (no systematic education)
Number of subjects: 5890
Study: 3707872

Group type: EXPERIMENTAL
Intervention: 500 microamperes (50 Hz) electric currents, continuous exposure for 5.5 hours on the second day
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham exposure (control group)
Number of subjects: 76
Study: 29745073

Group type: EXPERIMENTAL
Intervention: Combination of colloid (10mg/kg) and crystalloid solutions
Number of subjects: 55

Group type: COMPARATOR
Intervention: Crystalloid solutions only
Number of subjects: 55
Study: 27917214

Group type: EXPERIMENTAL
Intervention: Treadmill walking exercise training for six months in addition to medical treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 80
Study: 23767772

Group type: EXPERIMENTAL
Intervention: VUKA family-based program (10 sessions over approximately 3 months)
Number of subjects: 65
Study: 21885212

Group type: EXPERIMENTAL
Intervention: Directly observed therapy (DOT)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 77
Study: 19951979

Group type: EXPERIMENTAL
Intervention: Deferasirox (Exjade) at an initial dose of 20 mg/kg/day for patients receiving 2‐4 packed red blood cell units/month, 10 mg/kg/day for patients receiving less frequent transfusions, and 30 mg/kg/day for patients receiving more frequent transfusions.
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: Deferasirox (Exjade) with dose adjustments based on 3‐month serum ferritin trends and continuous assessment of safety markers.
Number of subjects: 1744
Study: 18671874

Group type: EXPERIMENTAL
Intervention: Intermittent Preventive Treatment in infants (IPTi)
Number of subjects: 0
Study: 16848649

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 49
Study: 12914721

Group type: EXPERIMENTAL
Intervention: Gastric surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weight loss
Number of subjects: 0
Study: 11100392

Group type: EXPERIMENTAL
Intervention: Acupuncture at classic acupuncture points
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acupuncture at 'tender' points
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Placebo (minimal needling at non-acupuncture points)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (20 min rest)
Number of subjects: 48
Study: 8811150

Group type: EXPERIMENTAL
Intervention: 4 hours bed rest after sheath removal
Number of subjects: 86

Group type: COMPARATOR
Intervention: 6 hours bed rest after sheath removal
Number of subjects: 86
Study: 1422616

Group type: EXPERIMENTAL
Intervention: Clomipramine (225 mg/day from week 5)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phenelzine (75 mg/day from week 5)
Number of subjects: 30
Study: 3852899

Group type: EXPERIMENTAL
Intervention: Aspoxicillin (ASPC) 2 g administered intravenously twice a day for 7 days
Number of subjects: 154

Group type: COMPARATOR
Intervention: Sulbenicillin (SBPC) 2 g administered intravenously twice a day for 7 days
Number of subjects: 154
Study: 31928758

Group type: EXPERIMENTAL
Intervention: Moderate (MOD) feeding rate of milk replacer (0.64 to 0.66 kg of dry matter (DM)/d for the first 35 to 39 d)
Number of subjects: 491

Group type: COMPARATOR
Intervention: High (HI) feeding rate of milk replacer (0.92 to 1.07 kg of DM/d for the first 35 to 44 d)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Moderate (MOD) feeding rate of milk replacer
Number of subjects: 491

Group type: COMPARATOR
Intervention: High (HI) feeding rate of milk replacer
Number of subjects: 491
Study: 29097028

Group type: EXPERIMENTAL
Intervention: bezlotoxumab 10 mg/kg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: actoxumab 10 mg/kg + bezlotoxumab 10 mg/kg
Number of subjects: 95

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 95
Study: 26826355

Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin (IV OT) at doses of 0.1 IU/kg, 1 IU/kg, and 5 IU/kg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (IN OT) at doses of 0.1 IU/kg, 1 IU/kg, and 5 IU/kg
Number of subjects: 4
Study: 25680840

Group type: EXPERIMENTAL
Intervention: Lyophilized aqueous extract of M. officinalis leaves (500 mg twice a day for 14 days)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 22851045

Group type: EXPERIMENTAL
Intervention: Multimedia-supported education (MME)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard education (SE)
Number of subjects: 203
Study: 20386035

Group type: EXPERIMENTAL
Intervention: Videoconferencing
Number of subjects: 175

Group type: COMPARATOR
Intervention: Face-to-face office visits
Number of subjects: 175
Study: 18162446

Group type: EXPERIMENTAL
Intervention: Levocetirizine (5mg oral administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fexofenadine (internal standard)
Number of subjects: 0
Study: 16722397

Group type: EXPERIMENTAL
Intervention: E-selectin measured by enzyme linked immunosorbent assay in nasal polyps
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: E-selectin expression in vascular endothelial and matrix of nasal polyps
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Correlation of E-selectin expression in vascular endothelial and matrix
Number of subjects: 34
Study: 14518696

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (45 mg, 67.5 mg, or 90 mg twice daily) with background ARV regimen
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (background ARV regimen alone)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (combined groups)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (all doses)
Number of subjects: 71
Study: 10996576

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin nasal spray 200 IU
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Salmon calcitonin nasal spray 100 IU
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Salmon calcitonin nasal spray 400 IU
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin nasal spray (all active treatment groups)
Number of subjects: 1255
Study: 9105062

Group type: EXPERIMENTAL
Intervention: LTD4 (mean cumulative concentration: 95.7 microM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methacholine (mean cumulative concentration: 542 mM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diluent (PBS/ethanol or PBS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LTD4
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 12
Study: 1359803

Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg.kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: vecuronium 0.1 mg.kg‐1
Number of subjects: 30
Study: 3541420

Group type: EXPERIMENTAL
Intervention: 25 mg isosorbide‐5‐mononitrate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 50 mg isosorbide‐5‐mononitrate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 mg isosorbide‐5‐mononitrate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31576791

Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/day
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Cariprazine 3 mg/day
Number of subjects: 1383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1383
Study: 30265963

Group type: EXPERIMENTAL
Intervention: Rocker-soled shoes
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control shoes
Number of subjects: 31
Study: 29070158

Group type: EXPERIMENTAL
Intervention: SH plus MTA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SS plus MTA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SH plus CH
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SS plus CH
Number of subjects: 80
Study: 26385172

Group type: EXPERIMENTAL
Intervention: Prior iliac simulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prior iliac simulation
Number of subjects: 0
Study: 23339225

Group type: EXPERIMENTAL
Intervention: Iron supplementation (multivitamin with iron)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (multivitamin)
Number of subjects: 150
Study: 21832218

Group type: EXPERIMENTAL
Intervention: Pramipexole ER
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Pramipexole IR
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study: 19859954

Group type: EXPERIMENTAL
Intervention: Primary stent implantation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Balloon angioplasty (PTA)
Number of subjects: 73
Study: 17080880

Group type: EXPERIMENTAL
Intervention: Er:YAG laser + Clearfil tri‐S Bond (Kuraray)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Er:YAG laser + Clearfil Protect Bond (Kuraray)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Er:YAG laser + Single Bond 2 (3M‐ESPE)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional method + Clearfil Protect Bond
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional method + Clearfil tri‐S Bond
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional method + 37% H3PO4 + Single Bond 2
Number of subjects: 35
Study: 14981126

Group type: EXPERIMENTAL
Intervention: Removable long-bar overdentures
Number of subjects: 30

Group type: COMPARATOR
Intervention: Maxillary fixed prostheses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overdentures with palates
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overdentures without palates
Number of subjects: 30
Study: 11344712

Group type: EXPERIMENTAL
Intervention: FASTPAC (FP)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: SITA Standard (SS)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: SITA Fast (SF)
Number of subjects: 41
Study: 9046389

Group type: EXPERIMENTAL
Intervention: 0.25 g of ethanol/kg of body weight
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.50 g of ethanol/kg of body weight
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 6
Study: 9316697

Group type: EXPERIMENTAL
Intervention: Intravenous flumazenil
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 3238319

Group type: EXPERIMENTAL
Intervention: Glucagon (143 nmol i.v. bolus followed by 430 nmol infused at a constant rate over 90 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 8
Study: 31826827

Group type: EXPERIMENTAL
Intervention: Multi-parametric MRI-based radiomic model
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Multi-parametric MRI-based radiomic features
Number of subjects: 57
Study: 29659952

Group type: EXPERIMENTAL
Intervention: Type A diet adherence (tertile 3 compared with tertile 1)
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Type B diet adherence (tertile 3 compared with tertile 1)
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Type AB diet adherence (tertile 3 compared with tertile 1)
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Type A diet adherence after 6-month intervention
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Type B diet adherence after 6-month intervention
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Type O diet adherence after 6-month intervention
Number of subjects: 973
Study: 27140203

Group type: EXPERIMENTAL
Intervention: Oral iron polysaccharide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study: 25777546

Group type: EXPERIMENTAL
Intervention: Vitamin D3 2,000 IU
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Vitamin D3 4,000 IU
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (both doses)
Number of subjects: 57
Study: 24105303

Group type: EXPERIMENTAL
Intervention: Hypothermia group (loading dose of 4°C cold saline, cooled to 32°C to 34°C for 48 hours)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Hypothermia group
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Subgroup analysis on patients with pneumococcal meningitis
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Post hoc analysis
Number of subjects: 98
Study: 21176107

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) using reticulated open‐cell foam (ROCF)
Number of subjects: 21
Study: 18347627

Group type: EXPERIMENTAL
Intervention: Massage Device (MD)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Finger Massage (FM)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study: 17151173

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12697591

Group type: EXPERIMENTAL
Intervention: sevoflurane+nitrous oxide 60%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: isoflurane+air in oxygen 40%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: sevoflurane+air in oxygen 40%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: isoflurane+nitrous oxide 60%
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anaesthesia (thiopental 5 mg kg(‐1), fentanyl 3 micro g kg(‐1), vecuronium 0.08 mg kg(‐1))
Number of subjects: 40
Study: 10780136

Group type: EXPERIMENTAL
Intervention: Internet-delivered computer-assisted health education (CAHE) program (Student Bodies)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study: 8814511

Group type: EXPERIMENTAL
Intervention: Pedalling at 50 r.min‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pedalling at 90 r.min‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pedalling at 110 r.min‐1
Number of subjects: 8

Group type: COMPARATOR
Intervention: Comparison of W' at 50, 90, and 110 r.min‐1
Number of subjects: 8
Study: 1383821

Group type: EXPERIMENTAL
Intervention: MOPP alone for 6 to 8 cycles
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: MOPP alternating with ABVD for 12 cycles
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: ABVD alone for 6 to 8 cycles
Number of subjects: 361

Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 361

Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 361
Study: 6367375

Group type: COMPARATOR
Intervention: Preeclampsia
Number of subjects: 3

Group type: COMPARATOR
Intervention: Normotensive pregnancy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Pregnancy
Number of subjects: 3

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 3

Group type: COMPARATOR
Intervention: 3 months after delivery
Number of subjects: 3
Study: 31461390

Group type: EXPERIMENTAL
Intervention: Thematic frame
Number of subjects: 306

Group type: COMPARATOR
Intervention: Episodic frame
Number of subjects: 306
Study: 30405108

Group type: EXPERIMENTAL
Intervention: Plant-based diet (n=38)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control diet (n=37)
Number of subjects: 75